The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system

Diabetes and Vascular Disease Research

Volumn 11, Issue 5, 2014, Pages 306-323

  Schernthaner, Guntram ^a   Mogensen, Carl Erik ^b   Schernthaner, Gerit Holger ^c  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Diabetic nephropathy; glomerular filtration rate; incretin; renal impairment; type 2 diabetes

Indexed keywords

ACARBOSE; ALBUMIN; ANTILIPEMIC AGENT; CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ALBUMINURIA; ANEMIA; BLOOD PRESSURE REGULATION; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK FACTOR; SMOKING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ENZYMOLOGY; KIDNEY; METABOLISM; TREATMENT OUTCOME;

ALBUMINURIA; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; KIDNEY; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84906043294     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114542802     Document Type: Review

References (98)

1. International Diabetes Federation (IDF). IDF diabetes atlas. 6th ed.Brussels: IDF, 2013, http://www.idf.org/diabetesatlas (accessed 6 November 2013).
2. Parving H-H, Mauer M, Ritz E Brenner and rector's the kidney. 7 th ed.Philadelphia, PA: W.B. Saunders, 2004, pp.1777-1818. BM Brenner, ed. Philadelphia, PA: W.B. Saunders ; 2004: 1777-1818.
3. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008 ; 4: 444-452
4. Rossing K. Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring. Dan Med Bull. 2007 ; 54: 79-98
5. SaydahSEberhardtMRios-BurrowsN. Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep2007; 56: 161-165, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5608a2.htm#tab (accessed 6 November 2013).
6. Centers for Disease Control and Prevention (CDC). Chronic kidney disease surveillance system - United States. U.S.Department of Health and Human Services, http://www.cdc.gov/ckd (accessed 6 May 2014).
7. Amato D, Alvarez-Aguilar C, Castaneda-Limones R, et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int. 2005 ; 68: S11 - S17
8. Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2003 ; 42: 22-35
9. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005 ; 16: 180-188
10. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003 ; 41: 1-12
11. Fox CS, Larson MG, Vasan RS, et al. Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol. 2006 ; 17: 521-527
12. Garg AX, Papaioannou A, Ferko N, et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int. 2004 ; 65: 649-653
13. Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006 ; 69: 2155-2161
14. Kramer H, Toto R, Peshock R, et al. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol. 2005 ; 16: 507-513
15. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003 ; 63: 1121-1129
16. McClellan W, Warnock DG, McClure L, et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. J Am Soc Nephrol. 2006 ; 17: 1710-1715
17. Brugts JJ, Knetsch AM, Mattace-Raso FU, et al. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005 ; 165: 2659-2665
18. Cirillo M, Laurenzi M, Mancini M, et al. Low glomerular filtration in the population: prevalence, associated disorders, and awareness. Kidney Int. 2006 ; 70: 800-806
19. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006 ; 17: 2275-2284
20. Nitsch D, Felber Dietrich D, von Eckardstein A, et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant. 2006 ; 21: 935-944
21. Otero A, Gayoso P, Garcia F, et al. Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study. Kidney Int. 2005 ; 99: S16 - S19
22. Verhave JC, Gansevoort RT, Hillege HL, et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int. 2004 ; 92: S18 - S21
23. Viktorsdottir O, Palsson R, Andresdottir MB, et al. Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. Nephrol Dial Transplant. 2005 ; 20: 1799-1807
24. Wasen E, Isoaho R, Mattila K, et al. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med. 2004 ; 256: 70-78
25. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003 ; 14: S131 - S138
26. Chen J, Wildman RP, Gu D, et al. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years. Kidney Int. 2005 ; 68: 2837-2845
27. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005 ; 16: 791-799
28. Konta T, Hao Z, Abiko H, et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int. 2006 ; 70: 751-756
29. Li ZY, Xu GB, Xia TA, et al. Prevalence of chronic kidney disease in a middle and old-aged population of Beijing. Clin Chim Acta. 2006 ; 366: 209-215
30. McDonald SP, Maguire GP, Hoy WE. Renal function and cardiovascular risk markers in a remote Australian Aboriginal community. Nephrol Dial Transplant. 2003 ; 18: 1555-1561
31. Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005 ; 68: 228-236
32. Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006 ; 164: 263-271
33. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008 ; 8: 117
34. U.S. Renal Data System. USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, http://www.usrds.org/atlas.aspx (accessed 6 November 2013).
35. Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006 ; 69: 2057-2063
36. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia. 2006 ; 49: 11-19
37. Equiluz-Bruck S, Schnack C, Kopp HP, et al. Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus. Am J Hypertens. 1996 ; 9: 1139-1143
38. Knobl P, Schernthaner G, Schnack C, et al. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993 ; 36: 1045-1050
39. Kramer CK, Leitão CB, Pinto LC, et al. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007 ; 30: 1998-2000
40. Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012 ; 7: 401-408
41. Hsieh MC, Hsieh YT, Cho TJ, et al. Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control. Eur J Clin Invest. 2011 ; 41: 870-878
42. Standards of medical care in diabetes - 2013. Diabetes Care. 2013 ; 36: S11 - S66
43. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012 ; 60: 850-886
44. Schernthaner G. Kidney disease in diabetology: lessons from 2010. Nephrol Dial Transplant. 2011 ; 26: 454-457
45. Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care. 2011 ; 34: S330 - S334
46. Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes. 2011 ; 60: 298-305
47. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-2572
48. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010 ; 160: 785-794
49. Athyros VG, Mitsiou EK, Tziomalos K, et al. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother. 2010 ; 11: 723-730
50. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006 ; 17: 2006-2016
51. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005 ; 45: 281-287
52. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003 ; 63: 1499-1507
53. Silverberg DS, Wexler D, Iaina A, et al. Anemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol. 2006 ; 38: 295-310
54. Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep. 2007 ; 7: 449-453
55. Afshinnia F, Wilt TJ, Duval S, et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2010 ; 25: 1173-1183
56. Phisitkul K, Hegazy K, Chuahirun T, et al. Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci. 2008 ; 335: 284-291
57. Patel A, Group AC, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 ; 370: 829-840
58. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary. Endocr Pract. 2013 ; 19: 536-557
59. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011 ; 54: 280-290
60. Sarafidis PA, Stafylas PC, Georgianos PI, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis. 2010 ; 55: 835-847
61. Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013 ; 36: S155 - S161
62. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012 ; 33: 187-215
63. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors - from preclinical development to clinical research. Kidney Blood Press Res. 2012 ; 36: 65-84
64. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci. 2013 ; 124: 17-26
65. Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009 ; 122: S3 - S10
66. Russell-Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int J Clin Pract. 2010 ; 64: 1402-1414
67. Schernthaner G, Avogaro A, Schernthaner GH. Glycemic targets and antidiabetic drug treatment in patients with chronic kidney disease (stages 3-5). Hot Topics Diabetes. 2013 ; 1: 13-24
68. Huttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008 ; 48: 1171-1178
69. Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?. Nephrol Dial Transplant. 2010 ; 25: 2044-2047
70. Ryuge A, Minoru K, Yu K, et al. Examination of the effects of liraglutide on diabetic nephropathy. Kidney Res Clin Pract. 2012 ; 31: A70
71. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011 ; 58: 69-73
72. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 ; 369: 1317-1326
73. Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013 ; 36: 3460-3468
74. Von Eynatten M, Emser A, Cooper ME, et al. Renal safety and outcomes with linagliptin: meta-analysis of individual data for 5466 patients with type 2 diabetes. J Am Soc Nephrol. 2012 ; 23: 218A
75. Komala MG, Panchapakesan U, Pollock C, et al. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens. 2013 ; 22: 113-119
76. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001 ; 280: F10 - F18
77. Bays H. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther. 2013 ; 4: 195-220
78. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014 ; 8: 262-275
79. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013 ; 1: 208-219
80. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013 ; 36: 2508-2515
81. Farxiga (package insert).Princeton, NJ: Bristol-Myers Squibb (last updated January2014), http://packageinserts.bms.com/pi/pi-farxiga.pdf (accessed 10 April 2014).
82. Invokana (package insert). Titusville, NJ: Janssen Pharmaceuticals, Inc. (last updated May2014), http://www.invokanahcp.com/prescribing-information.pdf (accessed 29 June 2014).
83. Macha S, Mattheus M, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. J Diab Res Clin Met. 2012 ; 1: 14
84. De Nicola L, Gabbai FB, Liberti ME, et al. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014 ; 64: 16-24
85. Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney Int. 2013 ;:
86. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 ; 15: 463-473
87. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014 ; 85: 962-971
88. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 ; 2: 369-384
89. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013 ; 382: 941-950
90. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009 ; 32: 650-657
91. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2013 ;:
92. Coelln-HoughJHortonEMeiningerG. FDA Canagliflozin Advisory Committee Meeting - Endocrinologic and Metabolic Drugs Advisory Committee, 10January2013, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM336236.pdf (accessed 14 May 2014).
93. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells - renoprotection in diabetic nephropathy?. PLoS One. 2013 ; 8: e54442
94. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014 ; 306: F194 - F204
95. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 ; 129: 587-597
96. Kramer H, Molitch ME. Screening for kidney disease in adults with diabetes. Diabetes Care. 2005 ; 28: 1813-1816
97. Heerspink HJ, Holtkamp FA, de Zeeuw D, et al. Monitoring kidney function and albuminuria in patients with diabetes. Diabetes Care. 2011 ; 34: S325 - S329
98. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011 ; 86: 444-456